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The increasing in-
cidence of cardio-
vascular disease
and the relatively
low level of pre-
ventive and thera-
peutic services in
low/middle income
countries points to
the importance of
concerted health
care efforts in this
part of the world,
both for global
health and the
global economy.We live in a world of constant change and evolution, and this is certainly trueof health care. With the passage of time, major changes are occurring in thescience, delivery, and funding of medicine. Nowhere in medicine are such
transformations greater than in cardiovascular disease. The scientific advances in cardiol-
ogy in my lifetime have been extraordinary, and there is very little that I do these days
that I did as a resident or fellow. These advances also brought with them alternations in
the prevalence of disorders, the nature of practice, and the systems and finances of deliv-
ering clinical care. In many respects, the changes occurring in cardiovascular medicine
are even greater outside of the United States, especially in the developing world.
To keep abreast of the changes that are taking place, the American College of Cardi-
ology has commissioned a document called the Environmental Scan that provides infor-
mation and statistics regarding the prevalence, diagnosis, therapy, and policy issues of
cardiovascular disease worldwide. We published this document as a Supplement in De-
cember, 2012 (1). It provides fascinating data in regard to the alterations that are under-
way in the United States, but even more interesting facts about the state of cardiovascu-
lar disease in the rest of the world. It seemed to me that much of this information was
worthy of reflection.
The enormity of cardiovascular disease and the financial burden it imposes upon soci-
ety continues to amaze me. Heart attack, stroke, and hypertension have long been the
major causes of death in the industrialized (high income) world, but now are increas-
ingly prevalent even in the developing (low and middle income) world. Noncommunica-
ble diseases have now overtaken communicable diseases as the major cause of death in
the world, and cardiovascular disease accounts for nearly half of such deaths and half of
the economic losses due to them. Mortality due to cardiovascular disease is rapidly increasing
in low and middle income countries, where it occurs at a younger age and has a greater eco-
nomic effect. Increasing cardiovascular mortality in low/middle income countries is likely to
continue since the prevalence of hypertension and smoking is greatest there. In addition,
increasing urbanization in the developing world will likely bring with it less exercise, expo-
sure to environmental pollution, and a more atherogenic diet. The United States has the
dubious distinction of leading the world in the greatest increase in body mass index. The
World Health Organization estimates that failure to implement prevention and therapy for
cardiovascular disease could result in a cost of $47 trillion in the next 25 years, a cost that
will be borne more heavily by low and middle income countries since they account for 80%
of cardiovascular deaths. The increasing incidence of cardiovascular disease and the relatively
low level of preventive and therapeutic services in low/middle income countries points to the
importance of concerted health care efforts in this part of the world, both for global health
and the global economy.
An aging population represents another challenge to the health care system. Statistics
demonstrate that average life expectancy is increasing throughout the world, even in
countries with an average annual income of $10,000. The implications of aging upon
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population over 65 years is highest in Western Europe
and Asia (Japan and Korea), countries in which it is an-
ticipated to increase the most over the next 30 years. It is
also worthy of note that the United States ranks 27th in
life expectancy in the world.
An important factor influencing health in the United
States and worldwide is the physician workforce. In the
United States, one-third of surveyed physicians plan to
retire in the next 10 years and the American Association
of Medical Colleges estimates that the country will be
short from 90,000 to 130,000 physicians by 2025. In the
absence of corrective measures, it is estimated that there
could be a national shortage of 15,000 general cardiolo-
gists by 2025. The need for additional manpower exists
for all subspecialties, including interventional cardiology,
electrophysiology, pediatric cardiology, and cardiac sur-
gery. The cardiovascular manpower may be influenced by
the relatively small number of women in the field, al-
though that number is increasing rapidly. The problem is
also accentuated by the geographic variability in the dis-
tribution of physicians, which is greatest in the northeast
and less in the southeast and west.
It appears that the shortage of physicians in high in-
come countries has had a detrimental effect upon man-
power in the low/middle income countries. It was esti-
mated that 1.5 million health care professionals from
developing countries were working in industrialized na-
tions. In the United States graduates of foreign medical
schools make up 30% of the cardiology manpower, and
account for approximately the same percentage of those in
cardiovascular training programs. The exodus of highly
trained medical personnel is, of course, an enormous eco-
nomic loss to developing countries. Given the increasing
incidence of cardiovascular disease in low/middle income
countries, the lack of medical professionals to provide care
is particularly distressing. It seems paradoxical that high
income countries with great resources are siphoning off
desperately needed physicians and nurses from countries
with much fewer resources and an already existent short-
age of such individuals.
The availability of new pharmaceutical agents also plays
a significant role in global cardiovascular health. In this
regard, the growth of pharmaceutical sales has fallen in
recent years. Many of the leading drugs used to treat car-
diac disease such as atorvastatin and clopidogrel have
come off patent, leading to an estimated loss of $78 bil-
lion worldwide. Interestingly, the loss of revenues to ge-neric drugs, which has been beneficial to patients needing
these agents, has been offset by greater sales in the devel-
oping world. Despite the continued high prevalence of
cardiovascular disease, there are only approximately 150
new agents under development for these disorders, com-
pared to nearly 700 under development for cancer. Data
indicate that growth is more robust for cardiac devices,
where the introduction of new stents and percutaneous
treatments for valvular heart disease such as transcatheter
aortic valve replacement continues to be brisk. Neverthe-
less, slowing in the introduction of new cardiovascular
drugs is a definite cause for concern in the cardiology
community.
There is much more interesting data and many more
fascinating statistics in the Worldwide Environmental
Scan (1). It provides useful information regarding many
of the changes underway in the funding of health care in
the United States, and of the prevalence of cardiometa-
bolic risk factors. However, what was most striking to me
was the increasing incidence and importance of cardiovas-
cular disease in the developing world. Given the greater
prevalence of heart attacks and strokes, and the absence of
extensive medical capabilities, cardiovascular disease in
low/middle income countries seems to be “low hanging
fruit” for effective intervention. The relocation of physi-
cian manpower from, and growth of the pharmaceutical
markets, in low/middle income countries attests to the
global health care interdependence of countries world-
wide. As John Donne said in his famous poem, “no man
is an island, entire of itself, each is a piece of the conti-
nent, a part of the main” (2). It will do us all well to in-
creasingly think of cardiovascular disease in a worldwide
perspective, and to pursue scientific, clinical care, and pol-
icy changes accordingly.
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